Kamada Ltd.

KMDA Healthcare Drug Manufacturers Specialty & Generic

Kamada Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $180.5 million, up 12.1% from fiscal 2024.

Revenue
+22.7%
EPS
+23.1%
Free cash flow
+165.7%
Total debt
−38.8%

Quarter to June 2026, against a year earlier

7.22 0.35 +5.09%
Market cap
$396.3M
P/E
18.1×
Fwd P/E
0.0×
Dividend yield
6.10%
F-score
7/9
Altman Z
3.33
Beneish M
−2.35
Dividend safety
50/100

Kamada Ltd. (KMDA) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, Kamada Ltd. (KMDA) trades at a P/E ratio of 18.1×. Over the past ten years it has ranged from 0.0× (June 2023) to 72.9× (August 2023); the current reading is higher than 60% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 20.5× and below the Healthcare sector median of 25.2×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 20.2× (13.88%)
FY2024 23.4× (39.16%)
FY2023 38.5× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 16.6× 31.37%
FY2019 12.6× 39.13%
FY2018 9.1× (67.80%)
FY2017 28.2× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 19.3× (18.94%)
Mar 2026 23.8× 18.13%
Dec 2025 20.2× 4.64%
Sep 2025 19.3× (15.43%)
42 more quarters

Against its own ten years

Low 0.0× High 72.9×
Ten-year median 13.7×
Current reading's percentile 36

P/E ratio against peers

Company P/E ratio
EBS Emergent Biosolutions Inc. compare n/m
TKNO Alpha Teknova, Inc. compare n/m
AQST Aquestive Therapeutics, Inc. compare n/m
ACB Aurora Cannabis Inc. compare n/m
EVO Evotec AG compare n/m
TLRY Tilray Brands, Inc. compare n/m
EOLS Evolus, Inc. compare n/m
CGC Canopy Growth Corporation compare n/m
KMDA Kamada Ltd. 18.1×
Drug Manufacturers Specialty & Generic industry median 20.5×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on KMDA